The Board of GeNeuro

Jesùs Martin-Garcia

Jesus holds a Bs in Business Administration, a Ms in Law from the University of Geneva and a MBA from Harvard Business School. Jesùs is a highly successful entrepreneur who has created, invested in and developed several technology-focused start-ups such as VTX, Silverwire and LeShop, Switzerland’s largest e-commerce company that he co-founded in 1997. Jesus began his career at McKinsey & Co where he managed teams in the pharma and consumer goods industries. He is a director of Eclosion. Jesus is the Chairman of the Board of GeNeuro.



Dr. Andrew Parker

Andrew has twenty years of experience in drug discovery and early development delivering novel small molecules and biologics into clinical development. Before joining Eclosion2 as a General Partner he was most recently VP and Head of Shire's Exploratory Projects Group developing novel therapies for specialty and rare disease indications. Andrew began his drug discovery career with Janssen Pharmaceutica followed by 11 years with AstraZeneca before becoming Head of Research at Opsona Therapeutics. Andrew has a Ph.D from the National Institute for Medical Research, carried out post-doctoral studies at Johns Hopkins School of Medicine and completed an MBA with Warwick Business School.

Jean-Jacques Laborde

Jean-Jacques Laborde is a Chemical Engineer and is a graduate from ESSEC Paris (École Supérieure des Sciences Économiques et Commerciales). He started his career at Servier and then joined Lazard Frères where he spent most of this career in the Merger & Acquisition department.

Jean-Jacques has been mainly involved in key healthcare transactions and has been in charge of the Investment Committee of Eurazeo for several years.

Jean-Jacques is currently Deputy General Manager of Institut Merieux.

Michel Dubois

Michel is a Director at GeNeuro SA, President of GeNeuro Innovation SAS. He is also a Director at Stallergénes and at the Hospital St Luc St Joseph in Lyon. Michel is Honorary Consul of Canada in Lyon. He was the Director General of Institut Mérieux and a consultant at McKinsey and Arthur Andersen.

Dr. François Curtin

François graduated with an MD from Geneva Medical School and obtained a Master in Philosophy in Medical Statistics from the London School of Hygiene and Tropical Medicine. He has a MBA from Warwick Business School.  After several years in academia, he joined Swissmedic, the Swiss Medicine Agency where he was responsible for the registration and market surveillance of neuropsychiatric drugs. Then, he joined Serono SA, then Merck Serono SA, where he worked in clinical and business development. Since 2009, François is the CEO of GeNeuro.


Dr. Hervé Perron  

Hervé has a PhD in Virology and a Professoral Thesis in Neuroimmunology. He is the author of over 120 peer-reviewed publications and patents and is referee for various scientific journals. He was Research Director of R&D within bioMérieux for the development of in vitro diagnostics in the domain of Neurological diseases. Hervé was Scientific Director of bioMérieux STELHYS, a spin-off dedicated to the evaluation of developments of upstream research projects. Hervé is a co-founder and Chief Scientific Officer of GeNeuro and the general manager of GeNeuro-Innovation.


Giacomo di Nepi

Giacomo was Executive Vice President and Managing Director for InterMune in Europe, where he built the European organization and led the launch of Esbriet® one of the most successful orphan drug launches in Europe. From 2006 to 2008, Giacomo was CEO of Takeda Pharmaceuticals, Europe. Between 1996 and 2006, he held various roles with Novartis, most recently as a Member of the Pharma Executive Committee and Global Head of the Transplantation, Immunology and Infectious Diseases Business Unit after being CEO of Novartis Italy. Giacomo had been a Partner with McKinsey & Co. and he served as Vice President of Farmindustria, the Italian Industry Association, and as a member of the EFPIA Heads of Europe Committee. Giacomo holds a degree in Economics from Bocconi University, Milan, and an MBA from INSEAD, Fontainebleau.


Dr. Gordon Francis 

Gordon is a neurologist with outstanding expertise in the treatment of Multiple Sclerosis. He has played a key role in the approval of several leading MS drugs. As Vice President, Therapeutic Area Head, Neurology with Novartis, Gordon was responsible for the development and registration of Gilenya®, the world’s first oral MS treatment. Prior to Novartis, he led the team responsible for the approval and launch of Tysabri® at Elan; and earlier, he spearheaded the approval of Rebif® with Serono. Gordon previously headed the MS Clinical Research Clinic at McGill and the Clinical Research Center at the Montreal Neurological Institute. He graduated from Queen’s University medical school in Kingston, completed Internal Medicine and Neurology training at McGill University and post-doctoral NeuroImmunology training at UCSF. Gordon has published over 100 peer reviewed articles in the field of neurology.